Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07439211 · ClinicalTrials.gov registry record · Phase 1
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Jacqueline Garcia, MD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT07439211 is a Phase 1 study that has not yet begun recruiting, run by Jacqueline Garcia, MD. The registered enrollment target is 48 participants.
The verdict
NCT07439211, a Phase 1 study, has not yet begun recruiting, sponsored by Jacqueline Garcia, MD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research study are: * Venetoclax (a type of BCL-2 inhibitor) * Azacitidine (a type of Demethylating Agent) * Eganelisib (a type of PI3K-gamma inhibitor)
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Eganelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07439211
The ClinicalTrials.gov registry entry for NCT07439211 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jacqueline Garcia, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT07439211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07439211 about?
NCT07439211 is a clinical study titled "Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia". This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research ...
What is the current status of trial NCT07439211?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-07. Estimated completion is 2029-02-01.
What interventions are being tested in trial NCT07439211?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Eganelisib (DRUG).
Who is sponsoring clinical trial NCT07439211?
This trial is sponsored by Jacqueline Garcia, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.